| Name | KTX-955 |
|---|---|
| Synonyms | 2-Pyridinecboxamide, N-[2-[trans-4-[[4-[[trans-3-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]cyclobutyl]oxy]-1-piperidinyl]methyl]cyclohexyl]-6-(1-hydroxy-1-methylethyl)-2H-indazol-5-yl]-6-(trifluoromethyl) |
| Description | KTX-955 is a potent IRAK4 degrader with DC50 values of 5 nM and 130 nM for IRAK4 and Ikaros, respectively. KTX-955 can be used to research anticancer[1][2]. |
|---|---|
| Related Catalog | |
| Target |
IRAK4:5 nM (IC50) |
| In Vitro | KTX-955 (compound I-312) degrades IRAK4 in OCI-LY10 at 24 hours with an IC50 of <0.05 μM[1]. |
| References |
[2]. Nello Mainolfi, et al. Irak degraders and uses thereof. WO2020264499A1 |
| Molecular Formula | C46H51F3N8O7 |
|---|---|
| Molecular Weight | 884.94 |